Regeneron Pharmaceuticals, Inc. (LON: 0R2M)

London flag London · Delayed Price · Currency is GBP · Price in USD
701.00
-6.30 (-0.89%)
Dec 23, 2024, 11:01 AM BST
-17.29%
Market Cap 60.06B
Revenue (ttm) 10.33B
Net Income (ttm) 3.47B
Shares Out n/a
EPS (ttm) 30.16
PE Ratio 17.30
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6
Open 701.00
Previous Close 707.30
Day's Range 701.00 - 701.00
52-Week Range 689.00 - 998.57
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 3, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1988
Employees 13,450
Stock Exchange London Stock Exchange
Ticker Symbol 0R2M
Full Company Profile

Financial Performance

In 2023, Regeneron Pharmaceuticals's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.

Financial numbers in USD Financial Statements

News

Regeneron reports positive results for two anti-coagulant drugs

Regeneron (REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to initiate Phase 3 testing next year.

3 days ago - Seeking Alpha

Regeneron Pharmaceuticals Inc (REGN) Announces Positive Phase 2 Results for Novel ...

Regeneron Pharmaceuticals Inc (REGN) Announces Positive Phase 2 Results for Novel Antithrombotic Antibodies

4 days ago - GuruFocus

Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results

Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations an...

4 days ago - GlobeNewsWire

Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January ...

5 days ago - GlobeNewsWire

Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study

Regeneron's EYLEA HD met key goals in the ... Full story available on Benzinga.com

5 days ago - Benzinga

Regeneron Pharmaceuticals Inc (REGN) Announces Positive Phase 3 Trial Results for EYLEA HD

Regeneron Pharmaceuticals Inc (REGN) Announces Positive Phase 3 Trial Results for EYLEA HD

6 days ago - GuruFocus

Regeneron Pharmaceuticals Inc (REGN) Achieves High Sustainability Rankings

Regeneron Pharmaceuticals Inc (REGN) Achieves High Sustainability Rankings

6 days ago - GuruFocus

Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year

TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI Worl...

6 days ago - GlobeNewsWire

Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDA...

13 days ago - Accesswire

Regeneron Pharmaceuticals Inc (REGN) Showcases Promising Results for Odronextamab in Lymphoma Trials

Regeneron Pharmaceuticals Inc (REGN) Showcases Promising Results for Odronextamab in Lymphoma Trials

13 days ago - GuruFocus

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the conf...

13 days ago - GlobeNewsWire

Regeneron Pharmaceuticals, Inc. Being Investigated on Behalf of Regeneron Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ...

14 days ago - Accesswire

Regeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Poze-Cemdi ...

Regeneron Pharmaceuticals Inc (REGN) Announces Promising Phase 3 Trial Results for Poze-Cemdi in PNH Treatment

15 days ago - GuruFocus

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydroge...

15 days ago - GlobeNewsWire

Regeneron: Recent Bear Run May Be Justified - Pharma Faces A Testing 2025

Regeneron Pharmaceuticals, Inc.'s stock faces challenges with Eylea's decline but potential growth from Dupixent. Find out why I maintain a Hold rating on REGN.

16 days ago - Seeking Alpha

Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ...

16 days ago - Accesswire

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

BENSALEM, Pa. , Dec. 6, 2024 /PRNewswire/ -- Law Offices of Howard G.

16 days ago - PRNewsWire

Levi & Korsinsky Reminds Shareholders of an Investigation into Regeneron Pharmaceuticals, Inc. (REGN) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ...

17 days ago - Accesswire

Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Piper Sandler 36th Annual Healthcare Conference Call December 5, 2024 9:30 AM ETCompany ParticipantsRyan Crowe...

17 days ago - Seeking Alpha

“Laggard” stocks with expanding FCF margins and attractive FCF yields – Goldman

Goldman Sachs listed their best free cash flow ideas, including Biogen (BIIB), Merck & Co. (MRK), and Regeneron Pharma (GEGN).

17 days ago - Seeking Alpha

REGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Regeneron Pharmaceuticals, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ...

18 days ago - Accesswire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

LOS ANGELES, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, ...

18 days ago - GlobeNewsWire

Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Navitas Semiconductor Corporation (NASDAQ: NVTS) is “ losing a lot of money.” On Tuesday, Navitas Semiconductor announced that Dr. Ranbir Singh ...

19 days ago - Benzinga

Lightning Round: I prefer Eli Lilly over Regeneron

'Mad Money' host Jim Cramer weighs in on stock including: Navitas, Regeneron and Landbridge.

19 days ago - CNBC